Private Wealth Partners LLC Takes $1.54 Million Position in Edwards Lifesciences Corporation

Analysts await Edwards Lifesciences Corp (NYSE:EW) to report earnings on February, 7.

Private Wealth Partners LLC purchased a new position in Edwards Lifesciences Corporation (NYSE:EW) in the 3rd quarter, according to its most recent 13F filing with the Securities & Exchange Commission. Koch Industries Inc. now owns 1,397,254 shares of the medical research company's stock valued at $1,386,000 after buying an additional 1,392,345 shares during the last quarter. B & T Capital Management DBA Alpha Capital Management boosted its position in shares of Edwards Lifesciences Corporation by 2.5% during the second quarter. BNP Paribas Arbitrage SA now owns 137,404 shares of the medical research company's stock worth $15,020,000 after acquiring an additional 41,694 shares during the period. Jennison Associates LLC grew its holdings in Edwards Lifesciences Corporation by 6.2% during the third quarter. The Cohen Lawrence B holds 53,005 shares with $6.27 million value, down from 61,625 last quarter. Checchi Capital Advisers LLC increased its stake in Edwards Lifesciences 3.9% in the second quarter. The stock rose 1.34% or $1.39 reaching $105.24 per share. Norinchukin Bank The now owns 11,106 shares of the medical research company's stock valued at $1,108,000 after buying an additional 93 shares during the period. The institutional investor held 78,877 shares of the major chemicals company at the end of 2017Q2, valued at $36.32M, up from 77,822 at the end of the previous reported quarter.

The top 5 institutional holders, in ascending order, are as follows: VANGUARD GROUP INC with 20.75 million shares, BLACKROCK INC. with 14.11 million shares, STATE STREET CORP with 9.1 million shares, SANDS CAPITAL MANAGEMENT, LLC with 7.63 million shares, and ALLIANCEBERNSTEIN L.P. with 5.96 million shares. (NYSE:EW) traded down 1.06% during midday trading on Tuesday, hitting $90.51. Edwards Lifesciences Corporation has had 8 insider trades in the last 3 months, including 0 open market buys and 8 sells. The company's P/E ratio is 30.52 and market cap is 22.22B. Nine analysts have provided estimates for Edwards Lifesciences Corporation's earnings, with estimates ranging from $0.88 to $0.92. The firm's 50 day moving average is $88.33 and its 200 day moving average is $105.03. Edwards Lifesciences Corporation had a net margin of 22.47% and a return on equity of 27.22%.

Edwards Lifesciences Corporation (NYSE:EW) last posted its quarterly earnings data on Tuesday, October 24th. Edwards Lifesciences Corp. The business had revenue of $739.40 million for the quarter, compared to the consensus estimate of $749.14 million. During the same period past year, the company earned $0.68 EPS. The company's revenue for the quarter was up 20.1% on a year-over-year basis. During the same quarter last year, the business posted $0.68 EPS. analysts expect that Edwards Lifesciences Corporation will post 3.75 earnings per share for the current year. Maintains Position in Edwards Lifesciences Corp. If you are accessing this news story on another site, it was copied illegally and reposted in violation of United States and worldwide trademark & copyright laws. Partner Investment Management Lp acquired 2,923 shares as Edwards Lifesciences Corp (EW)'s stock rose 25.80%.

Several brokerages have issued reports on EW. BidaskClub downgraded shares of Edwards Lifesciences Corporation from a "buy" rating to a "hold" rating in a research report on Friday, August 25th. BMO Capital Markets restated a "buy" rating and issued a $132.00 price target on shares of Edwards Lifesciences Corporation in a research report on Friday, September 1st.

Edwards Lifesciences Corporation (NYSE:EW) has seen its stock price gain 10.15, or +10.83%, so far in 2017. Of those analysts, 11 rate stock as a Strong Buy, 4 rate it as Hold, and just no analyst rates it as a Moderate Sell. Finally, Barclays PLC reaffirmed an "equal weight" rating and issued a $100.00 price objective on shares of Edwards Lifesciences a report on Saturday, December 10th. The stock saw a fall in short interest of -4.22% between October 13, 2017 and October 31, 2017. The total value of its holdings decreased 5.4%. William Blair reissued an "outperform" rating on shares of Edwards Lifesciences Corporation in a research report on Monday, August 28th. The stock was sold at an average price of $112.58, for a total transaction of $2,134,516.80. The disclosure for this sale can be found here.

Edwards Lifesciences Corporation is focused on technologies that treat structural heart disease and critically ill patients. The Firm offers a range of services to its customers, including design and development, engineering services, supply chain management, new product introduction, component sourcing, electronics manufacturing, assembly and test, complex mechanical assembly, systems integration, precision machining, order fulfillment, logistics and after-market fix and return services. It develops hemodynamic monitoring systems used to measure a patient's cardiovascular function in the hospital setting.

Like this


14 November 2017
Gareon Conley Reportedly Placed on IR by Raiders with Shin Injury
Amerson's return would help the Raiders, however much that may be, with Oakland sitting just outside the AFC playoff picture. He missed the entire preseason and the first game of the season. "He came in hitting the ground running".

14 November 2017
2 dead, 1 hurt after shooting in southwest Oklahoma City
The family of the 26-year-old victim drove in from Texas Monday afternoon after they learned of his passing. The female victim, later identified as 15-year-old Erica Bradberry, was pronounced dead at the scene.

14 November 2017
Cooper Tire & Rubber Company (NYSE:CTB)
Short traders are feeling a little more bearish on shares of the company of late if you take note of the change in short interest. KeyCorp also issued estimates for Cooper Tire & Rubber's Q4 2017 earnings at $0.63 EPS and FY2018 earnings at $3.80 EPS.

14 November 2017
Capcom Reportedly Bringing Three 'Ace Attorney' Games To Nintendo Switch
This of course has not been confirmed and is only a rumor at this point, but the sources we're hearing from are credible. Though this information is being reported from Kotaku UK , it should still be taken with a grain of salt.

14 November 2017
Striking college faculty across Ontario set to vote on final contract offer
Huckla said making up lost classes will likely mean students will lose their holiday break, and probably the spring break, too. Some 12,000 Ontario college professors, instructors, counsellors, and librarians haven't been at work since October 15.

14 November 2017
Paris Attack: Memories Return Again And Again, Loew Says
Toni Kroos and Sami Khedira will resume their World Cup-winning midfield partnership, Loew said. "I want to try things out against France".

14 November 2017
Advantus Capital Management Inc Grows Position in Stryker Corporation (SYK)
Finally, BidaskClub raised Stryker Corporation from a "hold" rating to a "buy" rating in a report on Thursday, August 17th. It dropped, as 38 investors sold SYK shares while 352 reduced holdings. 81 funds opened positions while 252 raised stakes.

14 November 2017
Eastman Chemical Company (EMN) Investment Increased by Td Asset Management Inc
A month ago, they told us to expect earnings of US$2.06 per share while three months ago their EPS consensus estimate was US$2.04. Td Asset Management Inc bought 52,381 shares last quarter increasing its exposure to Eastman Chemical Company by 8.4%.

14 November 2017
Moto X4 now in India at Rs 20999
Processor and RAM: Moto X4 is powered by an octa-core Snapdragon 630 SoC clocked at up to 2.2GHz, coupled with up to 4GB of RAM. Additionally, you can expand the storage to a whopping 2TB (although we don't recommend it) via the micro SD slot.

14 November 2017
GOP lawmakers tell Sessions to probe Clinton-Comey or resign
They said if it was so concerning, the director should have briefed the president-elect well before the January 6 briefing Mr. The conservative firebrands questioned Comey's role in the creation and distribution of the infamous Russian dossier.